AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Turpaz Industries Ltd.

Investor Presentation Nov 20, 2022

7098_rns_2022-11-20_c5934d28-419d-4857-b0de-2b045a61023f.pdf

Investor Presentation

Open in Viewer

Opens in native device viewer

INVESTOR PRESENTATION

1

November 2022

2

DISCLAIMER This presentation was prepared by Turpaz Industries Ltd. (the "Company") for the sole purpose of conveying information regarding the Company and its subsidiaries (together with the Company "Turpaz Group"). This presentation does not constitute, or form part of, an offer to sell, or a solicitation of an offer to purchase any securities of the Company and is intended to provide information only. This presentation is not intended to replace the need to review the Company's full reports to the Securities Authority and the Tel Aviv Stock Exchange Ltd. (hereinafter: "Company Reports") prior to making a decision regarding investment in the Company's securities.

In addition, this presentation cannot replace investment consulting by a lawfully licensed investment consultant.

This presentation includes statements data, forecasts, goals and Company plans that are "forward-looking statements", as defined in the Securities Law - 1968, whose occurrence is not certain, and which are not solely in the Company's control. These forward-looking statements are included, inter alia, in discussions of strategy, objectives, goals, plans, events, future intentions or other information relating to future events or issues whose occurrence is not certain.

By their nature, forward-looking statements involve risk and uncertainty. Whether the forward-looking information occurs or not is affected, inter alia, by risk factors characteristic to the Company's operations and developments in the general environment and external factors which impact the Turpaz Group and its area of activities.

Subject to the requirements of applicable law, the Company does not intend to update any industry information or forward-looking statements appearing in this presentation and is not required to publish any additional presentations for its shareholders in future.

9M YTD 2022 HIGHLIGHTS (M US \$)

Sales
\$ 88.1M
Gross profit
\$ 34.3M
Adjusted EBITDA
\$ 20.3M
+ 53.7% Sales growth
+ 14.7% Organic growth
+49.0% +42.7%
Enhanced and
expanded global
management to
support global
growth strategy
Solid balance sheet,
funding availability and
acquisitions strategy
8 acquisitions from
IPO (May 21) –
5 in 2022

Turpaz implemented a strategy of rapid double-digit growth, combining organic growth with synergistic and strategic acquisition while leveraging the synergies

9M YTD 2022 DOUBLE DIGIT GROWTH –

4 (*) based on the company's internal reporting

(**) Adj EBITDA - earnings before interest, taxes, depreciation, and amortization neutralization of one-time expenses of acquisitions and structural change.

Q3 2022 TURPAZ – CONSOLIDATED

In M US \$ / % Q3 2021 Q3 2022
Sales 17.8 30.3
Gross profit 7.2
40.7%
12.0
39.4%
Operating profit 3.4
19.2%
5
16.5% (*)
Adj. EBITDA 4.4 7.0

(*) Decrease in operating margin due to:

(1) Amortization of intangible assets

(2) Option share-based payment

(3) Recruitment of management teams and strengthening of the company's managerial infrastructure

In M US \$ / % Q3 2021 Q3 2022
Sales 5.1 6.7
Operating profit 1.9 2.1
37.1% 31.8%

Organic growth +13.8%

Highlights Strong organic growth

LORI profitability is lower than segment profitably. LORI has begun a program to improve its operational efficiency. Improved profitability is expected within the following quarters.

In M US \$ / % Q3 2021 Q3 2022
Sales 5.1 15.1
Operating profit 0.2
4.8%
2.2
14.3%

Organic growth

Highlights

+32.8%

Strong organic growth Profitably increased due to acquired companies' profitability and improvement of SDA's product lines & operational efficiency.

Q3 2022 PHARMA INTERMEDIATES P

In M US \$ / % Q3 2021 Q3 2022
Sales 6.0 5.3
Operating profit 2.0
33.2%
1.4
25.8%
Organic growth -4.7%
Highlights Profitability
mainly
affected
by
Euro
USD
impacts.

Q3 2022 SPECIALYY INGREDIENTS S

In M US \$ / % Q3 2021 Q3 2022
Sales 1.6 3.2
Operating profit 0.5
32.6%
0.9
29.3%
Organic growth +111.8%
Highlights Profitability
mainly
growth.
affected
by
strong
organic

P&L – SIGNIFICANT GROWTH

K US
\$
2021 Q3 2021 Q3 2022 YTD 9/2021 YTD 9/2022
Revenues 85,334 17,839 30,346 57,283 88,056
Gross Profit 34,728 7,256 11,950 23,036 34,314
GP% 40.7% 40.7% 39.4% 40.2% 39.0%
R&D Expenses 1,949 432 827 1,321 2,329
Sales & Marketing
expenses
6,274 1,143 2,496 3,831 7,010
Management &
General expenses
10,257 2,318 3,632 6,350 10,496
Other Expense
(Income)
208 (54) 3 113 )24(
Operating Profit 16,040 3,417 4,992 11,421 14,053
OP% 18.8% 19.2% 16.5% 19.9% 16.5%
Net Profit 12,812 2,522 3,591 8,839 11,790
EBIDTA 20,021 4,355 6,691 14,014 19,783
Adj. EBIDTA (*) 20,475 4,355 6,971 14,209 20,279
% Adj. EBIDTA 24.0% 24.4% 23.0% 24.8% 23.0%

BALANCE SHEET

K
US \$
30/9/2021 30/9/2022
Assets
Current Assets 99,110 92,944
Non-Current Assets 34,834 93,124
Total Assets 133,944 186,068
Liabilities & Equity
Current Liabilities 24,119 35,140
Non-Current Liabilities 25,821 60,061
Equity 84,004 90,867
Ratio
Working capital to sales 30.0% 30.5%
Cash and Cash equivalent 67,489 29,166
Net Cash (Net Debts)(*) 50,199 13,258
Equity to total balance sheet 62.7% 48.8%

Total Liabilities and Equity 133,944 186,068

Turpaz strong equity structure, low leverage, cash flow from operations, funding availability and the strengthening of management and managerial infrastructures enable the implementation of the group's combined growth strategy.

(*) Debts = Short and long-term loans from banks and other.

PROVEN TRACK RECORD OF ACQUISITIONS

* Completion expected in the coming weeks.

THANK YOU

Talk to a Data Expert

Have a question? We'll get back to you promptly.